www.ias2013.org kuala lumpur, malaysia, 30 june - 3 july 2013 access to hcv triple therapy with...
Post on 28-Mar-2015
216 Views
Preview:
TRANSCRIPT
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life
setting in HIV-HCV co-infected patientsANRS CO13 Hepavih Cohort
Poizot-Martin I., Gilbert C., Carrieri P., Miailhes P., Billaud E., Dominguez S., Dabis F., Sogni P., Loko M.-A., Salmon D*.
for the ANRS CO13 Hepavih group
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Background - Objectives
• First generation anti-HCV protease inhibitors (PI) available in France since 2011
• Triple therapy with these PI leads to a 30% increase of virological response compared to that of standard PegIFN + Ribavirin
• Our aim was to describe access to triple therapy and early results in a « real-life » prospective cohort of HIV-HCV co-infected patients
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Methods (1)
• ANRS CO13 Hepavih Cohort: • French prospective multicenter cohort
• 24 clinical centers
• 1324 HIV-HCV co-infected patients
• Population selection for analysis: • Positive HCV-RNA
• HCV genotype 1
• With at least one follow-up visit since January 2011
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Methods (2)
• Two groups of eligible patients were compared:
– One who initiated triple therapy
– And one who did not
• Virological response and tolerance to anti-HCV treatment were also evaluated
• Patients who stopped their treatment prematurely without virological data for the next visits were classified as virological failures
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Methods (3)
• Rapid virological response (RVR4):
– Undetectable (<15 UI/mL) HCV-RNA at week 4 after initiation*
• Early virological response:
- EVR12: Undetectable HCV-RNA at week 12*
• Severe anemia: - Hb <9 g/dL or a 4.5 g/dL decrease
* of triple therapy
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (1)
ANRS CO13 Hepavih cohort1st June 2013 database
N=1324
Eligible patients for analysisN=320
Initiation of a triple therapyN=114 (36%)
No triple therapyN=206 (64%)
Telaprevir n=81Boceprevir n=24Another molecule n=9
Outside clinical trials n=80(Telaprevir n=67, Boceprevir n=13)
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (3) Potential contra-indications to anti-HCV triple therapy
* Naïve or non responders to previous HCV treatment
§ Only few patients with available data
Initiation of anti-HCV triple
therapy
No anti-HCV triple therapy *
n (%) n (%) p
Psychiatric disorders 27 (23.7) 54 (26.2)
Current active drug use § 1 (2.9) 15 (9.2)
Alcohol > 5 units / day § 0 (0) 9 (5.3)
Non compatible HAART treatment 2 (1.8) 9 (4.6)
Cardiovascular disease 3 (2.6) 9 (4.4)
Decompensated cirrhosis or HCC 4 (3.5) 7 (3.4)
Platelets < 50 000/mm3 3 (2.7) 3 (1.5)
Renal insufficiency 3 (2.6) 5 (2.4)
Anemia (Hb <10 g/dL) 2 (1.8) 1 (0.5)
At least one contra-indication to triple therapy 39 (34.2) 86 (41.7) 0.191
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (4)
The 80 patients who initiated triple therapy outside clinical trials were evaluated for efficacy and safety>
100% received HAART with as 3rd agent:
Raltegravir: 43Atazanavir: 22Darunavir: 2Saquinavir: 2
Lopinavir :2Efavirenz: 7
Rilpivirine: 2
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
W4 W12 W24 W4 W12 W24
Telaprevir Boceprevir
020
4060
8010
0
2/10 6/10 6/10
20%
60% 60%
020
4060
8010
0
41/59 40/50 28/38
69%80%
74%
Results (5) Virological response
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Telaprevir
Genotype 1B
Results (6) Factors associated with VR24
Boceprevir
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
Genotype 1B
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
020
40
60
80
100
82%
9/11
68%
15/22
80%
4/5
020
4060
8010
0
67%
8/12
77%
20/26
020
4060
8010
0
69%
18/26
90%
9/10
020
4060
8010
0
63%
5/8
50%
1/2
020
4060
8010
0
50%
2/4
67%
4/6
020
40
60
80
100
0/0
60%
6/10 0/0
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (7) Virological response in cirrhotic non responders
Telaprevir Boceprevir
020
4060
8010
0
0/4 2/4 2/4
50% 50%
W4 W12 W24
020
4060
8010
0
12/20 10/15 6/10
60%67%
60%
W4 W12 W24
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (8) Virological response according to HAART
020
4060
8010
0
64%
18/28
73%
8/11
60%
3/5
100%
4/4
Raltegravir Atazanavir Efavirenz Others*
* Others = Darunavir, Saquinavir, Rilpivirine, Lopinavir
VR24
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (9) Adverse events during the first 12 weeks
Results are expressed as N (%) or median [IQR]
9 patients had a blood transfusion and 3 received EPO.
Telaprevirn=51
Boceprevirn=10
Anemia < 9 g/dl 18 (35%) 2 (20%)
Rash 8 (16%) 0 (0%)
Creatinine increase (µmol/L) +7 [-2,+10] +9 [+1,+33]
Pneumopathy 1 (2%) 0 (-)
Anal pruritus 4 (8%) 0 (-)
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Results (10) : Treatment interruptions
20/80 (25%) stopped their treatment prematurely
Median [IQR] treatment duration before stop: 4.6 months [2.7-6.25]
Reasons of treatment stop:
Telaprevir (n=15) Boceprevir (n=5)
Virological failure 10 (66.7%) 4 (80%)
Lung nodule 1 (6.7%) 0 (-)
Mood disorders 0 (-) 1 (6.7%)
Rash* 1 (6.7%) 0 (-)
Severe anemia 2 (13.3%) 0 (-)
Drug toxicity 1 (6.7%) 0 (-)
* Level 1
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Conclusion
Triple therapy was started despite potential contra-indications to treatment, mainly psychiatric disorders, present in 34% of treated patients. On the contrary, non treated patients did not have contra indications in 58% of the cases.
• Patients who initiated triple therapy with anti HCV PI were more often cirrhotic, and previously non responders to previous anti-HCV treatment, than patients who remained non treated.
• The rate of virological responses at W24 was high (74% for telaprevir and 60% for boceprevir), with a trend for a better VR in G1b and non cirrhotic patients.
• One must be cautious until assessment of sustained virological response as relapses can occur during the last months or after 48 weeks.
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Acknowledgments Patients of the HEPAVIH CohortScientific Committee of the ANRS CO13 HEPAVIH Study Group: D Salmon (principal investigator), F Dabis (principal investigator), M Winnock, MA Loko, P Sogni, Y Benhamou, P Trimoulet, J Izopet, V Paradis, B Spire, P Carrieri, C Katlama, G Pialoux, MA Valantin, P Bonnard, I Poizot-Martin, B Marchou, E Rosenthal, D Garipuy, O Bouchaud, A Gervais, C Lascoux-Combe, C Goujard, K Lacombe, C Duvivier, D Vittecoq, D Neau, P Morlat, F BaniSadr, L Meyer, F Boufassa, S Dominguez, B Autran, AM Roque, C Solas, H Fontaine, L Serfaty, G Chêne, D Costagliola, D Zucman, A Simon, E Billaud, P Miailhes, J Polo Devoto, L. Piroth, S Couffin-Cadiergues (ANRS). Clinical Centres (ward / participating physicians): CHU Cochin, Paris (Médecine Interne et Maladies Infectieuses / D Salmon, H Mehawej; Hépato-gastro-entérologie / P Sogni; Anatomo-pathologie / B Terris, Z Makhlouf, G Dubost, F Tessier, L Gibault, F Beuvon, E Chambon, T Lazure; Virologie / A Krivine); CHU Pitié-Salpétrière, Paris (Maladies Infectieuses et Tropicales / C Katlama, MA Valantin, H Stitou; Hépato-gastro-entérologie / Y Benhamou; Anatomo-pathologie / F Charlotte; Virologie / S Fourati); CHU Pitié-Salpétrière, Paris (Médecine Interne / A Simon, P Cacoub, S Nafissa; Anatomo-pathologie / F Charlotte; Virologie / S Fourati), CHU Sainte-Marguerite, Marseille (Service d'Immuno-Hématologie Clinique - CISIH/ I Poizot-Martin, O Zaegel; P Geneau, Virologie / C Tamalet); CHU Tenon, Paris (Maladies Infectieuses et Tropicales / G Pialoux, P Bonnard, F Bani-Sadr, L Slama, T Lyavanc; Anatomo-pathologie / P Callard, F Bendjaballah; Virologie / C Le-Pendeven); CHU Purpan, Toulouse (Maladies Infectieuses et Tropicales / B Marchou ; Hépato-gastro-entérologie / L Alric, K Barange, S Metivier; A Fooladi, Anatomo-pathologie / J Selves; Virologie / F Nicot); CHU Archet, Nice (Médecine Interne / E Rosenthal ; Infectiologie / J Durant; Anatomo-pathologie / J Haudebourg, MC Saint-Paul) ; CHU Avicenne, Bobigny (Médecine Interne – Unité VIH / O Bouchaud; Anatomo-pathologie / M Ziol; Virologie / Y Baazia); Hôpital Joseph-Ducuing, Toulouse (Médecine Interne / M Uzan, A Bicart-See, D Garipuy, MJ Ferro-Collados; Anatomo-pathologie / J Selves; Virologie / F Nicot); CHU Bichat – Claude-Bernard, Paris (Maladies Infectieuses / Y Yazdanpanah, A Gervais; Anatomo-pathologie / H Adle-Biassette); CHU Saint-Louis, Paris (Maladies infectieuses / JM Molina, C Lascoux Combe; Anatomo-pathologie / P Bertheau, J Duclos; Virologie / P Palmer); CHU Saint Antoine (Maladies Infectieuses et Tropicales / PM Girard, K Lacombe, P Campa; Anatomo-pathologie / D Wendum, P Cervera, J Adam; Virologie / N Harchi); CHU Bicêtre, Paris (Médecine Interne / JF Delfraissy, C Goujard, Y Quertainmont; Virologie / C Pallier); CHU Paul-Brousse, Paris (Maladies Infectieuses / D Vittecoq); CHU Necker, Paris (Maladies Infectieuses et Tropicales / O Lortholary, C Duvivier, M Shoai-Tehrani), CHU Pellegrin, Bordeaux (des Maladies Infectieuses et Tropicales / D Neau, A Ochoa, E Blanchard, S Castet-Lafarie, C Cazanave, D Malvy, M Dupon, H Dutronc, F Dauchy, L Lacaze-Buzy; Anatomo-pathologie / P Bioulac-Sage; Virologie / P Trimoulet, S Reigadas), Hôpital Saint-André, Bordeaux (Médecine Interne et Maladies Infectieuses / P Morlat, D Lacoste, F Bonnet, N Bernard, M Bonarek Hessamfar, J Roger-Schmeltz, P Gellie, P Thibaut, F Paccalin, C Martell, M Carmen Pertusa, M Vandenhende, P Mercier, D Malvy, T Pistone, M Catherine Receveur, S Caldato; Anatomo-pathologie / P Bioulac-Sage; Virologie / P Trimoulet, S Reigadas); Hôpital du Haut-Levêque, Bordeaux (Médecine Interne / JL Pellegrin, JF Viallard, E Lazzaro, C Greib; Anatomo-pathologie / P Bioulac-Sage; Virologie / P Trimoulet, S Reigadas), Hôpital FOCH, Suresnes (Médecine Interne / D Zucman, C Majerholc ; Virologie / F Guitard), CHU Antoine Béclère, Clamart (Médecine Interne / F Boue, J Polo Devoto, I Kansau, V Chambrin, C Pignon, L Berroukeche, R Fior, V Martinez; Virologie / C Deback), CHU Henri Mondor, Créteil (Immunologie Clinique / Y Lévy, S Dominguez, JD Lelièvre, AS Lascaux, G Melica), CHU Hôtel Dieu, Nantes (Maladies Infectieuses et Tropicales / F Raffi, E Billaud, C Alavena; Virologie / A Rodallec), Hôpital de la Croix Rousse, Lyon (Maladies Infectieuses et Tropicales/D Peyramond, C Chidiac, P Miailhes, F Ader, F Biron, A Boibieux, L Cotte, T Ferry, T Perpoint, J Koffi, F Zoulim, F Bailly, P Lack, M Maynard, S Radenne, M Amiri; Virologie / Le-Thi Than-Thuy); CHU Dijon, Dijon (Département d'infectiologie / P Chavanet, L Piroth, M Duong Van Huyen, M Buisson, A Waldner Combernoux, S Mahy, R Binois, A Laure Simonet Lann, D Croisier-Bertin) Data collection, management and statistical analyses: D Beniken, AS Ritleng, M Azar, P Honoré, S Breau, A Joulie, M Mole, C Bolliot, F Touam, F André, H. Roukas, C Partouche, G Alexandre, A. Mélard, , J. Baume, , H Hue, D Brosseau, C Brochier, V Thoirain, M Rannou, D Bornarel, S Gohier, C. Chesnel, S Gillet, J Delaune, C Gilbert, L Dequae-Merchadou, A Frosch, J Cohen, G Maradan, C Taieb, F Marcellin, M Mora, C Protopopescu, C Lions, MA Loko, M Winnock.
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Back-up slides
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Telaprevir
Genotype 1B
Boceprevir
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
Genotype 1B
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
HCV-RNA undetectable at W4 and W12
020
4060
8010
0
17%1/6 0/2
020
4060
8010
0
0/4
25%
1/4
020
40
60
80
100
0/013%1/8 0/0
020
40
60
80
100
67%
8/12
52%
15/29
100%
5/5
020
4060
8010
0
47%
8/17
69%
20/29
020
4060
8010
0
63%
20/32
64%
7/11
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Virological response
W4 W12 W24 W48 W4 W12 W24 W48
Telaprevir Boceprevir
020
4060
8010
0
41/59 40/50 28/38 12/27
69%80%
74%
44%
020
4060
8010
0
2/10 6/10 6/10 3/9
20%
60% 60%
33%
www.ias2013.org Kuala Lumpur, Malaysia , 30 June - 3 July 2013
Telaprevir
Genotype 1B
Boceprevir
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
Genotype 1B
Naïve Non responders
Relapsers
Genotype 1A
Cirrhotic Non- cirrhotic
HCV-RNA undetectable at W120
2040
6080
100
79%
27/34
92%
12/13
020
4060
8010
0
72%
13/18
84%
27/32
020
40
60
80
100
85%
11/13
74%
23/31
100%
6/6
020
4060
8010
0
63%
5/8
50%
1/2
020
4060
8010
0
50%
2/4
67%
4/6
020
40
60
80
100
0/0
60%
6/10 0/0
top related